Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company whose news flow centers on cancer drug development, regulatory milestones, and commercialization updates. The company’s announcements emphasize progress with its two FDA-approved therapies: Revuforj® (revumenib), an oral menin inhibitor for specific relapsed or refractory acute leukemias, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor-blocking antibody for chronic graft-versus-host disease after at least two prior systemic therapies.
News for SNDX often covers quarterly and annual financial results, product revenue trends for Revuforj and Niktimvo, and guidance on research and development as well as selling, general and administrative expenses. Investors can follow updates on clinical trial milestones, such as Phase 2 and Phase 3 studies of revumenib in newly diagnosed and relapsed or refractory NPM1-mutated and KMT2A-rearranged AML, and trials of axatilimab in chronic GVHD and idiopathic pulmonary fibrosis.
Press releases also highlight regulatory events, including FDA approvals and label expansions, inclusion of revumenib in clinical practice guidelines, and special designations such as Orphan Drug, Fast Track, and Breakthrough Therapy. Scientific and medical conference activity is another recurring theme, with multiple abstracts and oral presentations at meetings like the American Society of Hematology and appearances at investor conferences and healthcare forums.
In addition, Syndax issues news on collaborations and access initiatives, such as its agreement with the World Orphan Drug Alliance to launch a multi-regional Managed Access Program for Revuforj outside the United States. For investors and observers tracking SNDX, the news stream provides insight into commercial performance, pipeline evolution, partnership activity, and the company’s stated path toward profitability.
Syndax (Nasdaq: SNDX) reported $64.9M total revenue in 1Q26, including $48.9M Revuforj net revenue and $15.9M Niktimvo collaboration revenue. Cash, cash equivalents and short-term investments were $352.1M. Syndax posted a net loss attributable to common stockholders of $42.7M ($0.48/share). R&D was $58.8M and SG&A was $37.6M. The company expects combined R&D plus SG&A of ~$400M for 2026 (excluding ~$50M non-cash stock comp) and highlighted upcoming data readouts in 2Q26 and topline axatilimab Phase 2 data in 4Q26.
Syndax Pharmaceuticals (Nasdaq: SNDX) will report first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET.
Access the live audio webcast and slides via the Investors Events & Presentations page or use Conference ID Syndax1Q26 with domestic dial-in 800-590-8290 or international dial-in 240-690-8800. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement stock option awards on April 1, 2026, granting up to 228,500 shares to eight new employees under its 2023 Inducement Plan.
The options vest over four years: 25% at one year, then monthly vesting over 36 months, subject to continued service.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards granted on March 1, 2026. The company granted options to purchase up to 81,600 shares of common stock to three new employees under its 2023 Inducement Plan.
The options vest over four years: 25% after one year, then 1/48th monthly for 36 months, subject to continued service.
Syndax (NASDAQ: SNDX) reported Q4 2025 revenue $68.7M and FY2025 revenue $172.4M, driven by Revuforj net sales of $44.2M in Q4 ($124.8M FY2025) and Niktimvo net sales of $56.0M in Q4 ($151.6M FY2025).
The company had $394.1M in cash and equivalents at year-end, completed Phase 2 IPF enrollment for axatilimab, and expects 2026 R&D plus SG&A of ~$400M while targeting profitability from product and collaboration revenue.
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.
Syndax (Nasdaq: SNDX) will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET the same day.
Investors can join via the live webcast or dial in using the provided conference numbers and Conference ID. A replay will be posted on the Investors section of the company website approximately 24 hours after the call and will remain available for 90 days.
Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.
A live webcast and limited-time replay will be available in the company Investor section at www.syndax.com.
Syndax Pharmaceuticals (NASDAQ: SNDX) announced inducement equity awards granted on February 1, 2026 under its 2023 Inducement Plan. The company granted options to purchase up to 11,600 shares to two new employees.
The options vest over four years: 25% after one year and the remainder monthly (1/48th) over the following 36 months, subject to continued service.
Syndax (Nasdaq: SNDX) reported preliminary, unaudited 4Q25 and full‑year 2025 results and business updates ahead of its J.P. Morgan presentation on Jan 12, 2026.
Key figures: preliminary Revuforj net revenue of $44M in 4Q25 and $125M for 2025, Revuforj net revenue up ~38% in 4Q25 vs 3Q25; preliminary Niktimvo net revenue of $56M in 4Q25 and $152M for 2025. Year‑end cash and marketable securities approx. $394M. 2026 expense outlook: R&D plus SG&A ~$400M (ex‑$50M stock comp). Several Phase 2/3 trials and access programs planned for 2026.